Citadel Advisors
KALV

Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Citadel Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Buy
97,726
+59,965
+159% +$966K ﹤0.01% 6090
2025
Q4 		$610K Buy
+37,761
New +$500K ﹤0.01% 8558
2025
Q3 		– Sell
-15,841
Closed -$179K – 13473
2025
Q2 		$179K Buy
+15,841
New +$194K ﹤0.01% 10784
2025
Q1 		– Sell
-136,493
Closed -$1.39M – 15057
2024
Q4 		$1.16M Buy
136,493
+9,244
+7% +$95.7K ﹤0.01% 6723
2024
Q3 		$1.47M Buy
127,249
+108,427
+576% +$1.36M ﹤0.01% 6089
2024
Q2 		$222K Sell
18,822
-68,262
-78% -$797K ﹤0.01% 9704
2024
Q1 		$1.03M Sell
87,084
-696,614
-89% -$9.29M ﹤0.01% 6847
2023
Q4 		$9.6M Sell
783,698
-144,804
-16% -$1.32M ﹤0.01% 2903
2023
Q3 		$8.94M Buy
928,502
+81,896
+10% +$837K ﹤0.01% 2830
2023
Q2 		$7.62M Buy
846,606
+718,211
+559% +$6.62M ﹤0.01% 3042
2023
Q1 		$1.01M Buy
128,395
+26,868
+26% +$200K ﹤0.01% 6765
2022
Q4 		$686K Sell
101,527
-37,995
-27% -$204K ﹤0.01% 7581
2022
Q3 		$2.02M Sell
139,522
-33,759
-19% -$472K ﹤0.01% 5557
2022
Q2 		$1.71M Buy
173,281
+110,311
+175% +$1.22M ﹤0.01% 5873
2022
Q1 		$928K Buy
62,970
+45,564
+262% +$655K ﹤0.01% 7877
2021
Q4 		$230K Sell
17,406
-23,256
-57% -$370K ﹤0.01% 11558
2021
Q3 		$710K Sell
40,662
-35,186
-46% -$713K ﹤0.01% 9035
2021
Q2 		$1.82M Buy
75,848
+30,437
+67% +$796K ﹤0.01% 6839
2021
Q1 		$1.17M Buy
+45,411
New +$1.19M ﹤0.01% 7715
2020
Q2 		– Sell
-93,503
Closed -$715K – 10174
2020
Q1 		$715K Buy
+93,503
New +$1.26M ﹤0.01% 5894
2019
Q4 		– Sell
-10,194
Closed -$118K – 9434
2019
Q3 		$118K Sell
10,194
-10,878
-52% -$176K ﹤0.01% 8406
2019
Q2 		$467K Buy
+21,072
New +$494K ﹤0.01% 6925
2016
Q3 		– Sell
-1,923
Closed -$18K – 7490
2016
Q2 		$18K Buy
+1,923
New +$22.3K ﹤0.01% 6645
2015
Q3 		– Sell
-279
Closed -$28K – 9065
2015
Q2 		$28K Buy
+279
New +$27.7K ﹤0.01% 7996

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's KALV Position: Q1 2026 in Review

Citadel Advisors increased its KalVista Pharmaceuticals (KALV) stake by 159% in Q1 2026, buying an estimated $966K and bringing the position to 97,726 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #6090.

Citadel Advisors first reported a position in KALV in Q2 2015 and has held it in 24 quarters since. The position peaked at $9.6M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Citadel Advisors held 97,726 shares of KalVista Pharmaceuticals worth $1.97M as of Q1 2026.
  • Citadel Advisors bought 59,965 KalVista Pharmaceuticals shares in Q1 2026, an estimated $966K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6090 holding.
  • Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 24 quarters since.
  • Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.